OPTI-TEARS RED EYE 0.1 %
NAPHAZOLINE HYDROCHLORIDE : 0.1 % · DIN 02449609 · ALCON CANADA INC
Health Canada status: CANCELLED POST MARKET
What is OPTI-TEARS RED EYE?
OPTI-TEARS RED EYE 0.1 % contains NAPHAZOLINE HYDROCHLORIDE : 0.1 %. It is listed in the Health Canada Drug Product Database under DIN 02449609, held by ALCON CANADA INC, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as cancelled post market, status dated 22-Feb-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02449609 |
|---|---|
| Brand name | OPTI-TEARS RED EYE |
| Generic / active ingredient | NAPHAZOLINE HYDROCHLORIDE : 0.1 % |
| Manufacturer | ALCON CANADA INC |
| Strength | 0.1 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | S01GA01 NAPHAZOLINE |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 22-Feb-2024 |
What can be used instead?
Other Canadian products sharing ATC code S01GA01 NAPHAZOLINE. 2 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLEAR EYES | .012 % | LIQUID | PRESTIGE BRANDS INC | MARKETED | DIN 02248060 |
| COLLYRE BLEU LAITER | 0.2 MG | DROPS | FRILAB SA | MARKETED | DIN 00674354 |
| ALBALON | 0.1 % | DROPS | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 00001147 |
| CLEAR EYES BY MURINE EYE DPS | .012 % | LIQUID | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 00367036 |
| DIOPTICON LIQ 0.1% | 0.1 % | SOLUTION | PHARMA STULLN INC. | DORMANT | DIN 02026546 |
| NAPHCON FORTE | 0.1 % | SOLUTION | ALCON CANADA INC | CANCELLED POST MARKET | DIN 00390283 |
| ODAN-NAPHAZOLINE | .1 % | SOLUTION | ODAN LABORATORIES LTD | DORMANT | DIN 00626570 |
| OPCON OPH SOLN 0.1% | .1 % | DROPS | BAUSCH & LOMB CANADA INC. | CANCELLED POST MARKET | DIN 00750786 |
| R.O.-NAPHZ | .1 % | LIQUID | RICHMOND PHARMACEUTICALS INC. | CANCELLED POST MARKET | DIN 01901664 |
| RED AWAY | .1 % | LIQUID | RIVEX OPHTHALMICS INC. | CANCELLED POST MARKET | DIN 02212986 |
Who else supplies NAPHAZOLINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NAPHAZOLINE appears in 682 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.